Edition:
United Kingdom

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

18.21USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$18.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
415,573
52-wk High
$21.95
52-wk Low
$4.21

Chart for

About

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $1,341.42
Shares Outstanding(Mil.): 93.94
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update

02 Nov 2017

BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2

* Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2 Source text for Eikon: Further company coverage:

30 Oct 2017

BRIEF-Spectrum Pharma to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

* Spectrum Pharmaceuticals announces agreements to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

10 Oct 2017

BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility

* Spectrum Pharmaceuticals Inc provides update on at-the-market facility

29 Sep 2017

BRIEF-Spectrum Pharma starts phase 3 qapzola trial

* Spectrum pharmaceuticals announces initiation of the registrational phase 3 trial of qapzola™ (apaziquone) in patients with non-muscle invasive bladder cancer (nmibc)

14 Aug 2017

BRIEF-Spectrum Pharma enters into an at market issuance sales agreement

* Spectrum Pharmaceuticals Inc - on August 4, 2017, co entered into an at market issuance sales agreement - sec filing

04 Aug 2017

BRIEF-Spectrum Pharmaceuticals Q2 loss per share $0.26

* Spectrum Pharmaceuticals reports second quarter 2017 financial results and pipeline update

03 Aug 2017

BRIEF-Spectrum Pharmaceuticals announces ‍enrollment in Rolontis phase 3 advance pivotal study​

* Spectrum Pharmaceuticals Inc - ‍enrollment with 405 patients randomized in rolontis phase 3 advance pivotal study​

01 Aug 2017

BRIEF-Spectrum Pharmaceuticals says stockholders did not approve by advisory vote executive compensation at annual meeting

* Spectrum Pharmaceuticals Inc - stockholders did not approve by advisory vote executive compensation at annual meeting Source text: (http://bit.ly/2sHq6yo) Further company coverage:

16 Jun 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $141.14 +0.55
Pfizer Inc. (PFE.N) $36.21 +0.47
Novartis AG (NOVN.S) CHF83.35 +0.35
Merck & Co., Inc. (MRK.N) $56.34 --
Roche Holding Ltd. (ROG.S) CHF240.60 0.00
Roche Holding Ltd. (RO.S) CHF243.20 0.00
Abbott Laboratories (ABT.N) $54.94 --
Bayer AG (BAYGn.DE) €106.00 +0.85
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.82 +0.24

Earnings vs. Estimates